Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer
Although platinum-based chemotherapy remains the “standard” in advanced non small-cell lung cancer, not all patients derive clinical benefit from such a treatment. Hence, the development of predictive biomarkers able to identify lung cancer patients who are most likely to benefit from cisplatin-base...
Main Authors: | Christos Papadimitriou, Meletios-Athanasios Dimopoulos, Giannis Mountzios |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2008-01-01
|
Series: | Biomarker Insights |
Subjects: | |
Online Access: | http://la-press.com/article.php?article_id=712 |
Similar Items
-
Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer
by: Giannis Mountzios M.D., M.Sc., et al.
Published: (2008-01-01) -
Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study
by: Marina Piljić Burazer, et al.
Published: (2019-09-01) -
Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
by: Ning Tang, et al.
Published: (2017-06-01) -
Role of Nucleotide Excision Repair in Cisplatin Resistance
by: Mingrui Duan, et al.
Published: (2020-12-01) -
Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer — a pilot study
by: Janusz Milanowski, et al.
Published: (2012-04-01)